News & Events
Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
SAN DIEGO – July 13, 2017 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and...
READ MORECrinetics Pharmaceuticals Appoints Anne Klibanski, M.D. to Scientific Advisory Board
SAN DIEGO – November 10, 2016 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on specialty endocrine disorders and...
READ MORECrinetics Pharmaceuticals Appoints Ajay Madan as Vice President, Development
SAN DIEGO – June 6, 2016 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on specialty endocrine disorders, announced...
READ MOREThe San Diego Union-Tribune: Crinetics raises $40 Million
November 2, 2015 — Seeking to get its first drug ready for human testing, San Diego biotech Crinetics Pharmaceuticals has...
READ MOREXconomy: Crinetics Pharma Raises $40M in Comeback for Ex-Neurocrine Bio Team
November 2, 2015 — After spending the past six years scavenging for lab equipment and operating on a shoestring, San...
READ MORECrinetics Pharmaceuticals Completes $40 Million Series A Financing
SAN DIEGO – November 2, 2015 – Crinetics Pharmaceuticals, an innovative therapeutics company focused on specialty endocrine disorders, announced today...
READ MORECrinetics Pharmaceuticals Appoints Matt Fust, M.B.A., David Clemons, M.D., and John Wallen, Ph.D., J.D. as Corporate, Clinical, and Legal Advisers
SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers,...
READ MORECrinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain
SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers,...
READ MORECrinetics Pharmaceuticals Awarded $1.5MM NIH Phase-II SBIR Grant to Develop Kisspeptin Receptor Antagonists for PCOS and Other Women’s Health Diseases
SAN DIEGO — January 28, 2015 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a $1.5...
READ MORECrinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases
SAN DIEGO — April 28, 2014 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a Phase...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.